Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

Cell

Volumn 170, Issue 6, 2017, Pages 1120-1133.e17

  Wei, Spencer C ^a   Levine, Jacob H ^b   Cogdill, Alexandria P ^a   Zhao, Yang ^a   Anang, Nana Ama A S ^a   Andrews, Miles C ^a   Sharma, Padmanee ^a   Wang, Jing ^a   Wargo, Jennifer A ^a   Pe'er, Dana ^b   Allison, James P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

checkpoint blockade; costimulation; CTLA 4; host immune response; mass cytometry; melanoma; PD 1; T cell; tumor; tumor infiltrating lymphocyte

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PDCD1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LIMIT OF QUANTITATION; LYMPHOCYTE SUBPOPULATION; MASS CYTOMETRY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION; TUMOR GROWTH; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; PATHOLOGY; SINGLE CELL ANALYSIS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY; MELANOMA; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SINGLE-CELL ANALYSIS; T-LYMPHOCYTE SUBSETS; TRANSCRIPTION, GENETIC;

EID: 85028060533     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.07.024     Document Type: Article

References (58)

1. Amir, el-A.D., Davis, K.L., Tadmor, M.D., Simonds, E.F., Levine, J.H., Bendall, S.C., Shenfeld, D.K., Krishnaswamy, S., Nolan, G.P., Pe'er, D., viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat. Biotechnol. 31 (2013), 545–552.
2. Behbehani, G.K., Bendall, S.C., Clutter, M.R., Fantl, W.J., Nolan, G.P., Single-cell mass cytometry adapted to measurements of the cell cycle. Cytometry A 81 (2012), 552–566.
3. Bendall, S.C., Simonds, E.F., Qiu, P., Amir, A.D., Krutzik, P.O., Finck, R., Bruggner, R.V., Melamed, R., Trejo, A., Ornatsky, O.I., et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 332 (2011), 687–696.
4. + T cell exhaustion. Immunity 45 (2016), 358–373.
5. Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., Stankevich, E., Pons, A., Salay, T.M., McMiller, T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28 (2010), 3167–3175.
6. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
7. Carthon, B.C., Wolchok, J.D., Yuan, J., Kamat, A., Ng Tang, D.S., Sun, J., Ku, G., Troncoso, P., Logothetis, C.J., Allison, J.P., Sharma, P., Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16 (2010), 2861–2871.
8. Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28 (2017), 1368–1379.
9. Chemnitz, J.M., Parry, R.V., Nichols, K.E., June, C.H., Riley, J.L., SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J. Immunol. 173 (2004), 945–954.
10. Chen, H., Liakou, C.I., Kamat, A., Pettaway, C., Ward, J.F., Tang, D.N., Sun, J., Jungbluth, A.A., Troncoso, P., Logothetis, C., Sharma, P., Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc. Natl. Acad. Sci. USA 106 (2009), 2729–2734.
11. Chevrier, S., Levine, J.H., Zanotelli, V.R.T., Silina, K., Schulz, D., Bacac, M., Ries, C.H., Ailles, L., Jewett, M.A.S., Moch, H., et al. An immune atlas of clear cell renal cell carcinoma. Cell 169 (2017), 736–749.e718.
12. Curran, M.A., Montalvo, W., Yagita, H., Allison, J.P., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. USA 107 (2010), 4275–4280.
13. Das, R., Verma, R., Sznol, M., Boddupalli, C.S., Gettinger, S.N., Kluger, H., Callahan, M., Wolchok, J.D., Halaban, R., Dhodapkar, M.V., Dhodapkar, K.M., Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194 (2015), 950–959.
14. Daud, A.I., Loo, K., Pauli, M.L., Sanchez-Rodriguez, R., Sandoval, P.M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M.D., et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126 (2016), 3447–3452.
15. Fan, X., Quezada, S.A., Sepulveda, M.A., Sharma, P., Allison, J.P., Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J. Exp. Med. 211 (2014), 715–725.
16. Freeman, G.J., Long, A.J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L.J., Malenkovich, N., Okazaki, T., Byrne, M.C., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192 (2000), 1027–1034.
17. Gao, J., Shi, L.Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S.E., et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167 (2016), 397–404.e9.
18. Gubin, M.M., Zhang, X., Schuster, H., Caron, E., Ward, J.P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C.D., Krebber, W.J., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515 (2014), 577–581.
19. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
20. Huang, A.C., Postow, M.A., Orlowski, R.J., Mick, R., Bengsch, B., Manne, S., Xu, W., Harmon, S., Giles, J.R., Wenz, B., et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545 (2017), 60–65.
21. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
22. Im, S.J., Hashimoto, M., Gerner, M.Y., Lee, J., Kissick, H.T., Burger, M.C., Shan, Q., Hale, J.S., Lee, J., Nasti, T.H., et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537 (2016), 417–421.
23. Kamphorst, A.O., Pillai, R.N., Yang, S., Nasti, T.H., Akondy, R.S., Wieland, A., Sica, G.L., Yu, K., Koenig, L., Patel, N.T., et al. Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proc. Natl. Acad. Sci. USA 114 (2017), 4993–4998.
24. Koboldt, D.C., Zhang, Q., Larson, D.E., Shen, D., McLellan, M.D., Lin, L., Miller, C.A., Mardis, E.R., Ding, L., Wilson, R.K., VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22 (2012), 568–576.
25. Krummel, M.F., Allison, J.P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182 (1995), 459–465.
26. Latchman, Y., Wood, C.R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A.J., Brown, J.A., Nunes, R., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2 (2001), 261–268.
27. Lavin, Y., Kobayashi, S., Leader, A., Amir, E.D., Elefant, N., Bigenwald, C., Remark, R., Sweeney, R., Becker, C.D., Levine, J.H., et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169 (2017), 750–765.e717.
28. Leelatian, N., Doxie, D.B., Greenplate, A.R., Mobley, B.C., Lehman, J.M., Sinnaeve, J., Kauffmann, R.M., Werkhaven, J.A., Mistry, A.M., Weaver, K.D., et al. Single cell analysis of human tissues and solid tumors with mass cytometry. Cytometry B Clin. Cytom. 92 (2017), 68–78.
29. Levine, J.H., Simonds, E.F., Bendall, S.C., Davis, K.L., Amir, A.D., Tadmor, M.D., Litvin, O., Fienberg, H.G., Jager, A., Zunder, E.R., et al. Data-driven phenotypic dissection of AML reveals progenitor-like cells that correlate with prognosis. Cell 162 (2015), 184–197.
30. Li, H., Durbin, R., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25 (2009), 1754–1760.
31. Liakou, C.I., Kamat, A., Tang, D.N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., Sharma, P., CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl. Acad. Sci. USA 105 (2008), 14987–14992.
32. McGranahan, N., Furness, A.J., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C.T., et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351 (2016), 1463–1469.
33. Mei, H.E., Leipold, M.D., Maecker, H.T., Platinum-conjugated antibodies for application in mass cytometry. Cytometry A 89 (2016), 292–300.
34. Melchiotti, R., Gracio, F., Kordasti, S., Todd, A.K., de Rinaldis, E., Cluster stability in the analysis of mass cytometry data. Cytometry A 91 (2017), 73–84.
35. Newell, E.W., Cheng, Y., Mass cytometry: blessed with the curse of dimensionality. Nat. Immunol. 17 (2016), 890–895.
36. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12 (2012), 252–264.
37. Pauken, K.E., Sammons, M.A., Odorizzi, P.M., Manne, S., Godec, J., Khan, O., Drake, A.M., Chen, Z., Sen, D.R., Kurachi, M., et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354 (2016), 1160–1165.
38. Pounds, S., Morris, S.W., Estimating the occurrence of false positives and false negatives in microarray studies by approximating and partitioning the empirical distribution of p-values. Bioinformatics 19 (2003), 1236–1242.
39. Quezada, S.A., Peggs, K.S., Curran, M.A., Allison, J.P., CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116 (2006), 1935–1945.
40. Schadendorf, D., Hodi, F.S., Robert, C., Weber, J.S., Margolin, K., Hamid, O., Patt, D., Chen, T.T., Berman, D.M., Wolchok, J.D., Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33 (2015), 1889–1894.
41. Selby, M.J., Engelhardt, J.J., Quigley, M., Henning, K.A., Chen, T., Srinivasan, M., Korman, A.J., Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 1 (2013), 32–42.
42. Sharma, P., Allison, J.P., The future of immune checkpoint therapy. Science 348 (2015), 56–61.
43. Shekhar, K., Lapan, S.W., Whitney, I.E., Tran, N.M., Macosko, E.Z., Kowalczyk, M., Adiconis, X., Levin, J.Z., Nemesh, J., Goldman, M., et al. Comprehensive classification of retinal bipolar neurons by single-cell transcriptomics. Cell 166 (2016), 1308–1323.e1330.
44. Simpson, T.R., Li, F., Montalvo-Ortiz, W., Sepulveda, M.A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J.Y., Yagita, H., Wolchok, J.D., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210 (2013), 1695–1710.
45. Spitzer, M.H., Carmi, Y., Reticker-Flynn, N.E., Kwek, S.S., Madhireddy, D., Martins, M.M., Gherardini, P.F., Prestwood, T.R., Chabon, J., Bendall, S.C., et al. Systemic immunity is required for effective cancer immunotherapy. Cell 168 (2017), 487–502.e415.
46. Spitzer, M.H., Nolan, G.P., Mass cytometry: single cells, many features. Cell 165 (2016), 780–791.
47. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
48. Tanner, S.D., Baranov, V.I., Ornatsky, O.I., Bandura, D.R., George, T.C., An introduction to mass cytometry: fundamentals and applications. Cancer Immunol. Immunother. 62 (2013), 955–965.
49. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
50. Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366 (2012), 2443–2454.
51. Van der Auwera, G.A., Carneiro, M.O., Hartl, C., Poplin, R., Del Angel, G., Levy-Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics, 43, 2013 11.10.11-33.
52. van der Maaten, L., Hinton, G.E., Visualizing high-dimensional data using t-SNE. J. Mach. Learn. Res. 9 (2008), 2579–2605.
53. van Elsas, A., Hurwitz, A.A., Allison, J.P., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190 (1999), 355–366.
54. Walker, L.S., Sansom, D.M., The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11 (2011), 852–863.
55. Walunas, T.L., Lenschow, D.J., Bakker, C.Y., Linsley, P.S., Freeman, G.J., Green, J.M., Thompson, C.B., Bluestone, J.A., CTLA-4 can function as a negative regulator of T cell activation. Immunity 1 (1994), 405–413.
56. Wang, K., Li, M., Hakonarson, H., ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res., 38, 2010, e164.
57. Wolchok, J.D., Kluger, H., Callahan, M.K., Postow, M.A., Rizvi, N.A., Lesokhin, A.M., Segal, N.H., Ariyan, C.E., Gordon, R.A., Reed, K., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369 (2013), 122–133.
58. Zaretsky, J.M., Garcia-Diaz, A., Shin, D.S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D.Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375 (2016), 819–829.